Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Synergy Pharma provides corporate update ahead of presentation at the Leerink Partners 6th Annual Global Healthcare Conference (6.32 +0.02)<ul><li>Update on milestones<ul><li>Trulance in IBS-C — IBS-C sNDA filing expected this quarter</li><li>DOLCANATIDE in OIC — Potential lifecycle growth opportunity for Trulance</li><li>DOLCANATIDE in UC — Demonstrated POC</li></ul></li><li>Update on Trulance (Chronic Idiopathic Constipation) launch<ul><li>Established 'robust' supply chain process, trade and sample stock ready for launch this quarter, launching with 30-day blister pack</li><li>Finalized pricing strategy — launching at WAC price of $353.48</li></ul></li></ul></td> </tr></table>"